Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Lexapro (escitalopram oxalate) Tablets and Oral Solution October 2008

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.


Summary View

 

Sections Modified

ADVERSE REACTIONS

  • Events Reported Subsequent to the Marketing of Escitalopram
    • Cardiac Disorders
      • cardiac failure
    • Endocrine Disorders
      • diabetes mellitus
      • hyperprolactinemia
    • Gastrointestinal Disorder
      • rectal hemorrhage
    • Psychiatric Disorders
      • acute psychosis
    • Skin and Subcutaneous Tissue Disorders
      • urticaria
    • Vascular Disorders
      • deep vein thrombosis
      • phlebitis thrombosis

 

Label approved 10/11/2008 is not available on this site. 

-
-